A daily pill developed by the US pharmaceutical company Lilly may become a convenient alternative to injectable drugs like Ozempic and Wegovy. In phase III trials it significantly lowered blood sugar

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top executives met, like they had dozens of times before, to hear the long-awaited results of a study involving a new drug.